Patent · US Active

FGF21-FC fusion proteins for treating metabolic disorders

US10076554B2 · kind B2 · utility

2Cited by

2References

35Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Brian R. Boettcher · Winchester, US
Shari Lynn Caplan · Lunenburg, US
Douglas S. Daniels · Arlington, US
Norio Hamamatsu · Belmont, US
Stuart Licht · Cambridge, US
Stephen Craig Weldon · Leominster, US

Key dates

Filing date	Jan 4, 2016
Grant date	Sep 18, 2018
Priority date	—
Expiry date	Jan 4, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.